Chronic hepatitis C virus (HCV) infection has become a major health problem affecting an estimated 170 million people worldwide. The epidemiology of HCV and its response to treatment in Northern Ireland has not been described before. Our aims were to determine the epidemiology, histological stage, suitability for treatment and response to treatment in patients with hepatitis C presenting to one clinic in Northern Ireland. All patients were prospectively recruited with hepatitis C attending the Liver Clinic, Royal Victoria Hospital during the period December 1992 to June 1997. Sixty patients (33 male, mean age 44 years, range 19-84 years) who tested anti-HCV antibody positive were identified. The predominant genotypes were lb (33%), 3a (28%) and la (26%). Most patients (78 %) were asymptomatic at the time of detection and only four (7 %) gave a history of jaundice. The most common modes of transmission were i.v. drug use in 30 (50%) and blood products in 20 (33 %) patients. Forty-eight (86 %) of the 56 patients tested were PCR positive for HCV RNA. Fifty-one patients (85%) underwent liver biopsy of whom 13 had cirrhosis (22% of original group). Twenty-nine patients were suitable for treatment, but three declined treatment and only 26 (43%) started interferon-alpha. During treatment 17 (65%) patients became PCR negative and eight (31 %) remained PCR negative 12 months after completion of therapy. Liver histology was assessed before and after interferon treatment in 17 patients and showed no change in total necroinflammatory scores (p=0.1) or staging of architectural change (p=0.55). Conclusions: The epidemiology and response to therapy of HCV in Northern Ireland appear comparable to elsewhere in the UK. Only a minority of anti-HCV positive non-haemophiliac patients progress to have interferon therapy suggesting that the cost of treating chronic HCV may not be as great as initially thought.
INTRODUCTION
The hepatitis C virus (HCV) results in chronic hepatitis C (CHC) in up to 85% of those acutely infected.1 Chronic HCV infection has become a major health issue throughout the world affecting an estimated 170 million people.2 Up to one third of those with CHC will develop cirrhosis, and end-stage liver disease due to CHC is now the leading indication for liver transplantation worldwide. 3 The goal of therapy is obviously to prevent progression to end-stage liver disease with its consequences. Monotherapy with interferon alpha was the mainstay of treatment for CHC from the virus was first identified in 1989 until the late 1990's. Given the scale of the The Ulster Medical Journal HCV problem, the cost of treating most HCV patients is potentially enormous. However not all chronic HCV patients may be suitable for treatment and some have fairly indolent disease that does not require therapy. Despite over a decade of experience with HCV, debate continues regarding whom to treat and how. Studies have shown that a number of factors can influence response to therapy such as viral load and viral genotype. 4 There are six main HCV genotypes and genotype 1 is associated with a worse response to interferon therapy. liver biopsy and were medically fit to undergo treatment were offered interferon alpha therapy. Those patients who had decompensated cirrhosis, human immunodeficiency virus (HIV) infection, severe co-morbidity, pregnancy, continued intravenous drug abuse, other causes of chronic liver disease or who were PCR negative were excluded from treatment. Interferon alpha 2a was given as a starting dose of 3 million units (MU) subcutaneously thrice weekly for 1 month, then 4 MU thrice weekly for 1 month and finally up to 5 MU thrice weekly for 6 months with monthly monitoring of LFTs, FBP and HCV-RNA PCR. Patients who had difficulty with side-effects or a low platelet count due to interferon were maintained for 6 months on the maximum dose tolerated. On completion of therapy, LFTs and PCR were monitored every 3 months in those who had become PCR negative during treatment and a repeat liver biopsy was offered. Biopsies were independently scored by two pathologists who were blinded to the timing of each biopsy with relation to treatment. Each biopsy was scored for necroinflammation (0-18) and fibrosis (0-6) in accordance with the previously published modified Knodell Histology Activity Index for grading and staging of chronic hepatitis (Ishak et al, J Hepatol, 1995). Treatment response was defined as clearance of virus from the blood (PCR negative) and normalisation of ALT at completion of therapy and sustained viral response as the maintenance of this response at 6 months after completion of therapy.7
RESULTS
Sixty patients were recruited (33 male, mean age 44 years, age range 19-84 years). The most common genotypes were lb (33%), 3a (28%) and la (26% Early experience with chronic hepatitis C in Northern Ireland Perhaps not surprisingly, the epidemiology of chronic HCV in Northern Ireland (based on our study sample) is in keeping with the data described above. Allowances should be made for the fact that our study group excluded haemophiliac patients who mostly acquired HCV from blood products. Genotypes la and lb accounted for 57% of those whose genotype was tested and iv drug abuse was the most common risk factor accounting for halfofthe study group. As expected C The Ulster Medical Society, 2004 .
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The Ulster Medical Journal from other data, 1 in 10 people had no identifiable risk factor for HCV. The fact that at least 22% of the study group had cirrhosis at the time of presentation is probably in keeping with the widely quoted figure of 20-30% of chronic HCV patients developing cirrhosis within 20 years.1 This relatively high figure demonstrates the insidiously progressive nature of chronic HCV infection that can present many years after infection with advanced disease. Unfortunately we were unable to determine the length of time from initial HCV infection until presentation and therefore cannot comment on the mean time until development of cirrhosis.
The similarity between our study group demographics and other UK data 1 does not suggest that there should be any significant differences in response to treatment and the data bear this out. The initial response to interferon monotherapy treatment (61%) and subsequent sustained response rate (3 1 
